Please use this identifier to cite or link to this item:
Title: Hepatic safety of antibiotics used in primary care
Authors: Andrade Bellido, Raúl Jesús
Tulkens, Paul M
metadata.dc.contributor.authoraffiliation: [Andrade Bellido,RJ] Hepatology Unit, Gastroenterology Service, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Andrade Bellido,RJ] Department of Medicine, University of Málaga, Spain. [Andrade Bellido,RJ] Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Barcelona, Spain. [Tulkens,PM] Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. [Tulkens,PM] Human Biochemistry and Biochemical Pathology, Université de Mons, Belgium.
Keywords: Enfermedad Hepática Inducida por Drogas;Incidencia;Atención Primaria de Salud;Antibacterianos
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Substance-Related Disorders::Poisoning::Drug-Induced Liver Injury
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Health Care::Population Characteristics::Demography::Vital Statistics::Morbidity::Incidence
Medical Subject Headings::Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents
Issue Date: Jul-2011
Publisher: Oxford University Press
Citation: Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother.. 2011; 66(7):1431-46
Abstract: Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-induced hepatotoxicity. Most cases are idiosyncratic (the adverse reaction cannot be predicted from the drug's pharmacological profile or from pre-clinical toxicology tests) and occur via an immunological reaction or in response to the presence of hepatotoxic metabolites. With the exception of trovafloxacin and telithromycin (now severely restricted), hepatotoxicity crude incidence remains globally low but variable. Thus, amoxicillin/clavulanate and co-trimoxazole, as well as flucloxacillin, cause hepatotoxic reactions at rates that make them visible in general practice (cases are often isolated, may have a delayed onset, sometimes appear only after cessation of therapy and can produce an array of hepatic lesions that mirror hepatobiliary disease, making causality often difficult to establish). Conversely, hepatotoxic reactions related to macrolides, tetracyclines and fluoroquinolones (in that order, from high to low) are much rarer, and are identifiable only through large-scale studies or worldwide pharmacovigilance reporting. For antibiotics specifically used for tuberculosis, adverse effects range from asymptomatic increases in liver enzymes to acute hepatitis and fulminant hepatic failure. Yet, it is difficult to single out individual drugs, as treatment always entails associations. Patients at risk are mainly those with previous experience of hepatotoxic reaction to antibiotics, the aged or those with impaired hepatic function in the absence of close monitoring, making it important to carefully balance potential risks with expected benefits in primary care. Pharmacogenetic testing using the new genome-wide association studies approach holds promise for better understanding the mechanism(s) underlying hepatotoxicity.
Description: Journal Article; Review;
metadata.dc.identifier.doi: 10.1093/jac/dkr159
ISSN: 1460-2091 (Online)
0305-7453 (Print)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria

Files in This Item:
File Description SizeFormat 
Andrade_Hepatic.pdfArtículo publicado452,88 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons